JP2015523339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523339A5 JP2015523339A5 JP2015514446A JP2015514446A JP2015523339A5 JP 2015523339 A5 JP2015523339 A5 JP 2015523339A5 JP 2015514446 A JP2015514446 A JP 2015514446A JP 2015514446 A JP2015514446 A JP 2015514446A JP 2015523339 A5 JP2015523339 A5 JP 2015523339A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- atoms
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000001153 fluoro group Chemical group F* 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 229910052794 bromium Inorganic materials 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052740 iodine Inorganic materials 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims description 3
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BYBIRLURVZSVME-UHFFFAOYSA-M benzene;copper(1+);trifluoromethanesulfonate Chemical compound [Cu+].C1=CC=CC=C1.[O-]S(=O)(=O)C(F)(F)F BYBIRLURVZSVME-UHFFFAOYSA-M 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GRFNSWBVXHLTCI-UHFFFAOYSA-N 1-ethenyl-4-[(2-methylpropan-2-yl)oxy]benzene Chemical compound CC(C)(C)OC1=CC=C(C=C)C=C1 GRFNSWBVXHLTCI-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- QEMGMKHRBKOVHA-UHFFFAOYSA-N 4-tert-butyl-4,5-dihydro-1,3-oxazole Chemical compound CC(C)(C)C1COC=N1 QEMGMKHRBKOVHA-UHFFFAOYSA-N 0.000 description 1
- 0 C*(C=C(C(C1)C1C(O)=O)C=C1)C=C1OC(CC1)C(C=C2)=C1C(*)=CC2(C)N Chemical compound C*(C=C(C(C1)C1C(O)=O)C=C1)C=C1OC(CC1)C(C=C2)=C1C(*)=CC2(C)N 0.000 description 1
- BXEFQPCKQSTMKA-UHFFFAOYSA-N OC(=O)C=[N+]=[N-] Chemical compound OC(=O)C=[N+]=[N-] BXEFQPCKQSTMKA-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170057 | 2012-05-30 | ||
| EP12170057.9 | 2012-05-30 | ||
| PCT/EP2013/060844 WO2013178575A1 (en) | 2012-05-30 | 2013-05-27 | New indanyloxyphenylcyclopropanecarb oxylic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523339A JP2015523339A (ja) | 2015-08-13 |
| JP2015523339A5 true JP2015523339A5 (OSRAM) | 2016-07-21 |
| JP6163695B2 JP6163695B2 (ja) | 2017-07-19 |
Family
ID=48536855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514446A Active JP6163695B2 (ja) | 2012-05-30 | 2013-05-27 | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8633182B2 (OSRAM) |
| EP (1) | EP2855419B1 (OSRAM) |
| JP (1) | JP6163695B2 (OSRAM) |
| WO (1) | WO2013178575A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| RU2021109549A (ru) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
| JP6816107B2 (ja) * | 2015-08-07 | 2021-01-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
| CN107216317B (zh) * | 2016-03-21 | 2020-04-07 | 上海医药工业研究院 | 一种阿法替尼中间体的制备方法 |
| US10538490B2 (en) | 2016-10-25 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| EP3544958B1 (en) | 2016-11-28 | 2021-03-24 | Boehringer Ingelheim International GmbH | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| KR102007633B1 (ko) | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10603317B2 (en) | 2017-01-26 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110248929B (zh) * | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| WO2018138026A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110300755B (zh) | 2017-02-08 | 2022-10-04 | 勃林格殷格翰国际有限公司 | 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 |
| JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| DE60112268T2 (de) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| US7834013B2 (en) * | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| WO2005051373A1 (ja) * | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| ATE517867T1 (de) | 2005-02-15 | 2011-08-15 | Glaxo Group Ltd | Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin |
| WO2006103503A1 (en) | 2005-03-28 | 2006-10-05 | Pfizer Japan Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| JP4077028B2 (ja) | 2005-08-24 | 2008-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規ピリジン誘導体およびピリミジン誘導体（３） |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| US20090036473A1 (en) | 2006-03-15 | 2009-02-05 | William Dalby Brown | Novel quinazolinone derivatives and their medical use |
| PT2042480E (pt) | 2006-07-18 | 2013-06-24 | Astellas Pharma Inc | Derivado de aminoindano ou um seu sal |
| EP2289868B1 (en) | 2008-06-25 | 2014-08-13 | Daiichi Sankyo Company, Limited | Carboxylic acid compound |
| CN102137836B (zh) * | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | 用于治疗代谢疾病的化合物 |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| BRPI1007202A2 (pt) | 2009-01-22 | 2016-02-23 | Raqualia Pharma Inc | composto de fórmula (i), composição farmacêutica, método para tratamento de condição mediada pela atividade do receptor cb2 em um indivíduo mamífero e uso de composto de fórmula (i) |
| US8389580B2 (en) * | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| WO2010143733A1 (en) * | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| CN102883602B (zh) | 2010-02-16 | 2017-07-18 | Uwm研究基金会有限公司 | 降低细菌的毒力的方法 |
| AP2012006390A0 (en) | 2010-02-19 | 2012-08-31 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| AU2011281134B2 (en) * | 2010-07-23 | 2015-05-14 | Connexios Life Sciences Pvt. Ltd. | Agonists of GPR40 |
| CA2813639A1 (en) * | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
-
2013
- 2013-05-22 US US13/900,121 patent/US8633182B2/en active Active
- 2013-05-27 WO PCT/EP2013/060844 patent/WO2013178575A1/en not_active Ceased
- 2013-05-27 JP JP2015514446A patent/JP6163695B2/ja active Active
- 2013-05-27 EP EP13725649.1A patent/EP2855419B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523339A5 (OSRAM) | ||
| JP2013508279A5 (OSRAM) | ||
| JP2012521429A5 (OSRAM) | ||
| JP2018535963A5 (OSRAM) | ||
| JP2007523155A5 (OSRAM) | ||
| US20040259842A1 (en) | Intracellular calcuim concentration increase inhibitors | |
| JP2013505946A5 (OSRAM) | ||
| JP6709205B2 (ja) | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 | |
| JP2013512277A5 (OSRAM) | ||
| JP2013507423A5 (OSRAM) | ||
| JP2012521428A5 (OSRAM) | ||
| SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceutical products | |
| JP2011509309A5 (OSRAM) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| JP2016508506A5 (OSRAM) | ||
| JP2007507494A5 (OSRAM) | ||
| JP2017525699A5 (OSRAM) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2011516511A5 (OSRAM) | ||
| JP2015519322A5 (OSRAM) | ||
| WO2019244000A1 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of roryt | |
| JP2020517619A5 (OSRAM) | ||
| JP2015502371A5 (OSRAM) |